Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Assets (2016 - 2025)

Guided Therapeutics' Current Assets history spans 16 years, with the latest figure at $799000.0 for Q3 2025.

  • For Q3 2025, Current Assets fell 23.39% year-over-year to $799000.0; the TTM value through Sep 2025 reached $799000.0, down 23.39%, while the annual FY2024 figure was $1.2 million, 14.07% down from the prior year.
  • Current Assets for Q3 2025 was $799000.0 at Guided Therapeutics, down from $811000.0 in the prior quarter.
  • Across five years, Current Assets topped out at $3.5 million in Q3 2022 and bottomed at $799000.0 in Q3 2025.
  • The 5-year median for Current Assets is $1.4 million (2023), against an average of $1.6 million.
  • The largest annual shift saw Current Assets skyrocketed 705.04% in 2021 before it crashed 54.8% in 2023.
  • A 5-year view of Current Assets shows it stood at $1.6 million in 2021, then surged by 83.51% to $3.0 million in 2022, then plummeted by 53.63% to $1.4 million in 2023, then decreased by 14.07% to $1.2 million in 2024, then plummeted by 33.25% to $799000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Current Assets are $799000.0 (Q3 2025), $811000.0 (Q2 2025), and $811000.0 (Q1 2025).